Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Guess we'll wait for the penny. Or lower.
Reversal printing on the daily...
SNGX daily
Question is whether or not this market will let this get back over the $$.
Takes money to make money. 1st half 2022 should prove very interesting.
Excellent!! Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
Hepion Pharmaceuticals, Inc.
Tue, December 21, 2021, 5:00 AM·6 min read
In this article:
HEPA
0.00%
Explore the topics mentioned in this article
- New IND Expands Liver Disease Pipeline for CRV431 -
- IND Clearance Allows CRV431 to Move Directly into Phase 2 for Hepatocellular Carcinoma Treatment -
- New IND Provides for Complementary Therapeutic Approach of Treating NASH and Liver Cancer with a Single Once-a-Day Oral Agent -
EDISON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its investigational new drug (“IND”) application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (“HCC”).
On July 29, 2019, Hepion received FDA authorization of an IND to initiate the study of CRV431 for the treatment of NASH. To date, Hepion has completed Phase 1 studies in healthy volunteers and, more recently, announced positive data from its Phase 2a ‘AMBITION’ trial in subjects with presumed F2 and F3, where CRV431 was well tolerated, and all primary endpoints were met. A larger Phase 2b NASH study of over 300 subjects with paired liver biopsies, called ‘ASCEND-NASH’, is expected to be initiated in 2022. ASCEND-NASH will evaluate CRV431’s effects on the histologic endpoints of liver steatosis and fibrosis over 12 months dosing.
“Liver cancer is the sixth most prevalent cancer worldwide and is the second most common cause of cancer death,”1 commented Todd Hobbs, MD, Hepion’s Chief Medical Officer. “The most common form of liver cancer is HCC, which comprises about 90% of all liver cancers. Major risk factors associated with development of HCC include NASH, liver fibrosis and cirrhosis, viral hepatitis, chronic alcohol consumption, and metabolic syndrome. As the global prevalence of NASH is increasing, the incidence of HCC arising from NASH is also increasing. Approximately 25% to 30% of NASH-related HCC develops in the absence of cirrhosis and, therefore, occurs without many of the symptomatic warning signs of this aggressive form of cancer. An orally administered drug that simultaneously targets NASH and HCC would offer an advantageous therapeutic strategy to patients suffering these potentially life-threatening conditions. CRV431’s novel potential stems from its pleiotropic pharmacologic activities and from its ability to target the liver, allowing for a drug candidate ideally suited for the treatment of liver disease.”
Dr. Hobbs continued, “Another potentially important benefit is the patient experience while taking CRV431. Most cancer drugs are delivered by injection and are associated with significant side effects. In contrast, CRV431 is orally administered and has been shown to be well tolerated in clinical trials to date. We are optimistic that CRV431 may provide significant anti-cancer effects without imposing additional challenges and distress often associated with cancer drugs.”
Robert Foster, PharmD, PhD, Hepion’s CEO, said, “Increased cyclophilin isoform expression has been associated with negative outcomes in HCC. Importantly, CRV431 potently inhibits many of these isoforms in humans. Cyclophilins are enzymes that regulate many molecular and cellular activities that become dysregulated both in NASH and HCC. These dysregulated activities can lead to aberrations in signal transduction pathways, cell proliferation, cell death, extracellular environment including increased fibrosis, energy metabolism, inflammation, and immunity. Therapeutic intervention with CRV431 administration may reduce the pathologic potential associated with heightened cyclophilin activities in NASH and HCC, potentially allowing for a return to a healthier state.”
Dr. Foster continued, “CRV431 has shown anti-tumor activity in multiple animal studies, and our research team has been intensively investigating the specific mechanisms that have produced these outcomes. Our investigations have revealed interesting direct and indirect effects of CRV431 on cancer cells and tumors. For example, gene expression analyses have demonstrated CRV431’s ability to attenuate drug-resistance pathways and Wnt-ß-catenin-Myc signaling, the latter being mutationally over-activated in 30% to 50% of human HCC tumors. We recently also found that CRV431 increased lymphocyte infiltration into liver tumors in a manner similar to an immune checkpoint inhibitor, also known as an anti-PD-1 antibody, which is considered to be an important anti-tumor approach. We believe that the wide array of pharmacologic activities offered by CRV431 in the treatment of NASH and HCC should bode well for the further clinical development in both important indications.”
Reference
1Hepatocellular Carcinoma. Nature Reviews Disease Primers 7, 7 (2021).
About Hepion Pharmaceuticals
The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies.
Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission.
For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com
SNGX .7288
Daily chart
I like the looks, we'll see if this can pick up the momentum to make something happen though.
Sonnet BioTherapeutics Holdings (SONN) Gets a Buy Rating from H.C. Wainwright
December 21 2021 - 02:09AM
TipRanks
Print
Share On Facebook
H.C. Wainwright analyst Michael King reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report) yesterday and set a price target of $2.00. The company's shares closed last Monday at $0.47, close to its 52-week low of $0.43. According to TipRanks.com, King is a 5-star analyst with an average return of 20.2% and a 52.2% success rate. King covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Werewolf Therapeutics, and Compass Therapeutics. Sonnet BioTherapeutics Holdings has an analyst consensus of Strong Buy, with a price target consensus of $3.17, a 574.5% upside from current levels.
https://www.tipranks.com/news/blurbs/sonnet-biotherapeutics-holdings-sonn-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
CHAIRMAN, CEO AND PRESIDENT
https://ih.advfn.com/stock-market/NASDAQ/soligenix-SNGX/stock-news/86858716/statement-of-changes-in-beneficial-ownership-4
(1) This transaction was executed in multiple trades at prices ranging from $0.7399 to $0.74. The price reported above reflects the weighted-average purchase price.
Very interesting. Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases
ContraFect Corporation
Mon, December 20, 2021, 6:00 AM·8 min read
In this article:
CFRX
-3.20%
Data from Single Pediatric Patient Highlights that FDA-Designated Breakthrough Therapy Exebacase May be a Beneficial Adjunctive Therapy for Severe MRSA Infections in Children
YONKERS, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the recent publication of a case study report highlighting the potential of its first investigational direct lytic agent, exebacase, to treat methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in a pediatric population. The case report was published in the peer-reviewed Clinical Infectious Diseases, a journal of the Infectious Disease Society of America (IDSA).
“These data, although representing a single pediatric patient, provide a compelling case for further evaluation of exebacase in pediatric populations. These findings are especially important given the limited treatment options available to help address these life-threatening infections,” stated Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development of ContraFect Corporation. “We were pleased to learn of the positive outcome of this patient and we will continue to progress our critically important therapeutics as rapidly but as safely as possible.”
The results, published ahead-of-print, describe the pharmacokinetics (PK) and dosing of the first infant to receive exebacase. The patient, a previously healthy 5-month-old male infant, presented to Duke University Hospital for evaluation of jerking movements and inability to sit independently. Following a full evaluation, it was determined that he had a culture confirmed life-threatening MRSA infection with multi-organ involvement, included a left temporal subdural empyema, a retropharyngeal abscess, and right-sided endocarditis. Despite targeted therapy, optimized dosing, and attempts at source control, clearance of bacteremia and clinical improvement was not achieved with standard of care (SOC) antibiotics alone. The treating physician obtained authorization from the U.S. Food and Drug Administration (FDA) to use exebacase under an emergency individual patient investigational new drug application and the patient subsequently received one 3 mg dose of exebacase on hospital day 7. The patient continued to receive SOC anti-staphylococcal antibiotics throughout the hospital stay. Blood cultures became sterile on hospital day 12. The patient had ongoing clinical improvement and serial echocardiograms noted no evidence of heart valve vegetation on hospital day 40. The patient was discharged, without the need for additional surgery.
This report represents a single patient, and it is difficult to know with certainty if clinical improvement was due to exebacase directly, extended SOC antibiotic therapy or the combined effect of both. Nevertheless, exebacase is a novel DLA that may be a beneficial adjunctive therapy for MRSA bacteremia including right-sided endocarditis in children. Future clinical trials are planned to confirm dosing and efficacy in the pediatric population.
About Methicillin-Resistant Staphylococcus aureus (MRSA):
MRSA is a result of Staph aureus infections that are difficult to treat because of bacterial resistance to SOC antibiotics. MRSA bacteremia in particular causes significant morbidity and mortality. Treatment with SOC antibiotics alone is difficult due to increasing virulence, limited drug penetration, adverse events, and increasing resistance. New therapies for MRSA bacteremia are greatly needed.
About Exebacase (CF-301):
Exebacase is an anti-staphylococcal recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. It is the first lysin to enter clinical studies in the U.S. and was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.
Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis. In the Company’s Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates.
Exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia. Exebacase was licensed from The Rockefeller University and is being developed at ContraFect.
About ContraFect
ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the potential for exebacase to treat MRSA bacteremia in pediatric populations, ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, statements regarding exebacase and clinical improvement, whether exebacase may be a beneficial adjunctive therapy, planned pediatric clinical trials, whether MRSA bacteremia causes significant morbidity and mortality, whether exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect’s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect’s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption “Risk Factors” in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts:
Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com
Media:
Jules Abraham
CORE IR
Tel: 917-885-7378
Email: Julesa@coreir.com
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
Diffusion Pharmaceuticals Inc.
Thu, December 16, 2021, 8:59 AM·5 min read
In this article:
DFFN
+2.94%
Explore the topics mentioned in this article
Third of Three TSC Oxygenation Trials
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has dosed the first patients in its ILD-DLCO Trial. The trial will evaluate the Company’s lead product candidate, trans sodium crocetinate (“TSC”), in patients with previously diagnosed interstitial lung disease (“ILD”).
“We designed the ILD-DLCO Trial to evaluate the effects of TSC on the enhancement of oxygen uptake through the lungs and into the bloodstream of ILD patients,” said Chris Galloway, M.D., Chief Medical Officer of Diffusion. “This is the third of our Oxygenation Trials designed to evaluate the effects of TSC on the continuum of oxygen transport from uptake to delivery, and ultimately end organ utilization. We believe these data will provide further supportive information regarding TSC’s novel mechanism of action and dose-response characteristics and support the broad potential of TSC to treat a variety of conditions complicated by hypoxia.”
The ILD-DLCO Trial is a double-blind, randomized, placebo-controlled study which will evaluate the effects of TSC on the diffusion of carbon monoxide through the lungs (“DLCO”) in patients with previously diagnosed interstitial lung disease who have a baseline DLCO test result that is abnormal. DLCO will act as a surrogate measure of oxygen transfer efficiency, or uptake, from the alveoli of the lungs through the plasma, and onto hemoglobin within red blood cells. Diffusion intends to enroll 27 patients with confirmed ILD who will be randomized in a 2:1 ratio to a single 2.5mg/kg dose of TSC or placebo via IV bolus. The study is statistically powered to evaluate the difference in effect of TSC versus placebo on improvement in DLCO measurements. In addition, patients will undergo a standard six-minute walk test intended to assess functional improvement in exercise capacity. Diffusion anticipates completing the trial in the first quarter of 2022, with topline results reported within two months of study completion.
While the Company intends to continue developing data to support TSC’s potential uses across a broad spectrum of indications complicated by hypoxia, it recently announced that its near-term focus will be the design and execution of a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors, and that it intends to obtain input from the U.S. Food and Drug Administration on the program’s design in early 2022.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions, including hypoxic solid tumors. In November 2021, based on the preclinical and clinical data accumulated to date and the significant unmet medical need, Diffusion announced that its near-term focus will be the design and execution of a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors. For more information, please visit us at www.diffusionpharma.com.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s near-term strategic priorities, anticipated timelines for the initiation, completion, and announcement of data from the Company’s Oxygenation Trials and Hypoxic Solid Tumor Program, the relevance and significance of any such data, and the potential therapeutic value of TSC. The Company may, in some cases, use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, the Company’s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, among other things, those related to: the Company’s ability to design, initiate, enroll, execute, and complete its planned studies evaluating TSC; the likelihood and timing of regulatory approval of TSC, if any, for the treatment of solid tumors complicated by hypoxia or any other indication, or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration or other regulatory bodies; the impact of supply chain and other supplier issues on the Company’s clinical development program and associated timelines; the Company’s ability to protect and expand its intellectual property portfolio; the Company’s ability to maintain compliance with the continued listing standards of Nasdaq; general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and the other factors discussed under the heading “Risk Factors” in the Company’s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.
Contacts:
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA/ Lisa Sher
mmcenroe@tiberend.com/ lsher@tiberend.com
Media Contact:
Kate Barrette
RooneyPartners
Kbarrette@rooneypartners.com
Market Snapshot
MW Nasdaq slumps nearly 2%...
MarketWatch
1:44 pm ET
By William Watts and Mark DeCambre Bank of England delivers surprise interest rate increase, and ECB says it will further slow bond purchases U.S. stocks were putting in a mixed performance Thursday... Read more
S&P 500
4,663.12 46.73 (0.99%)
4pm
1pm
10am
4,730
4,695
4,660
Dow Jones Industrials
35,883.85 43.58 (0.12%)
4pm
1pm
10am
36,200
36,000
35,800
NASDAQ Composite
15,152.95 412.63 (2.65%)
Manipulated markets are sucking in retail. Don't know about you but my retirement funds are 90%+ cash. Gvt TSP.
My equity trading accounts are a wee bit RED.
Thinking even with Biden putting over a trillion $$$$ in the markets, with increasing inflation and rates it'll take some time to equalize which makes for fantastic volatility.
Know what you own. Keep price alerts set and never give up on trading.
LXRX low of 3.72 with a bounce almost back to $4.
Awesome, I'm bio heavy and tech moderate. So let's rock!!
Cheers and Happy Holidays!
And yes, I agree, the markets have been on a volatile down trend lately.
Potential short squeeze into earnings? It's rare imo, but it could happen.
Shake outs everywhere and then.... dead cat bounces everywhere.
Or is it finally time for the Santa rally!!!??
Filled 2.68 & another batch @ 2.70. The chart does not appeal to me, I'll say that.
Conference Call today @ 10AM...
Synthetic Biologics will hold a conference call today, December 14, 2021, at 10:00 a.m. Eastern Time. The dial-in information for the call is as follows, U.S. toll free: 1-888-347-5280 or International: +1 412-902-4280. Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/43946. An archive of the call will be available for replay at the same URL, https://www.webcaster4.com/Webcast/Page/1096/43946, for 90 days after the call.
https://ih.advfn.com/stock-market/AMEX/synthetic-biologics-SYN/stock-news/86803061/synthetic-biologics-announces-planned-transformati
This'll be interesting.
https://ih.advfn.com/stock-market/AMEX/synthetic-biologics-SYN/stock-news/86803061/synthetic-biologics-announces-planned-transformati
https://www.syntheticbiologics.com/news-media/press-releases/detail/314/synthetic-biologics-announces-planned-transformative
I like the vesting period and the no compete time frame. This is decent. See if they make us some mula!
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2021
INPIXON
(Exact name of registrant as specified in its charter)
Nevada 001-36404 88-0434915
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)
2479 E. Bayshore Road, Suite 195
Palo Alto, CA 94303
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (408) 702-2167
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock INPX The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 1.01 Entry into a Material Definitive Agreement.
On December 8, 2021, Inpixon (the “Company”), through its wholly-owned subsidiary, Nanotron Technologies GmbH, a limited liability company incorporated under the laws of Germany (the “Purchaser”), entered into that certain Share Sale and Purchase Agreement (the “Purchase Agreement”) with the shareholders (the “Sellers”) of IntraNav GmbH, a limited liability company incorporated under the laws of Germany (“IntraNav”), to acquire 100% of the outstanding capital stock (the “IntraNav Shares”) of IntraNav (the “Acquisition”). IntraNav is a leading industrial IoT (“IIoT”), real-time location system (“RTLS”), and sensor data services provider. All defined terms used herein and not otherwise defined have the meanings set forth in the Purchase Agreement.
On December 9, 2021 (the “Closing Date”), the Purchaser acquired the IntraNav Shares from the for an aggregate purchase price of EUR 1,000,000, subject to certain adjustments.
The Purchase Agreement includes customary representations and warranties, as well as certain covenants, including, inter alia, that the Managing Directors, so long as they are employees of the Purchaser, shall not, for a period of two (2) years following the Closing Date, directly or indirectly, compete with the Company in activities related to IIoT platforms and other RTLS solutions and technologies.
In addition, pursuant to the terms of the Purchase Agreement, the Company allocated 7,100,629 stock options (the “Stock Options”) from its 2018 Employee Stock Incentive Plan for issuance to IntraNav employees, which shall be subject to vesting terms of up to four (4) years from the Closing Date.
The Purchase Agreement provides for potential indemnification claims by the Purchaser against the Sellers, as applicable, subject to certain limitations and conditions. If such claims are made against the Founders, then such liability can, in the sole discretion of each Founder, be covered in cash or by forfeiting parts of their Stock Options, which will be valued in an amount equal to the Adjusted Strike Price determined as of the payment date of the claim amount.
The foregoing description of the Purchase Agreement does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
The Company has determined that the Acquisition does not constitute an acquisition of a significant amount of assets (as defined in Instruction 4 of Item 2.01) and, as such, financial statements contemplated by Item 9.01 of Form 8-K are not required to be reported by Form 8-K with respect to such acquisition.
(b) Pro forma financial information.
The Company has determined that the Acquisition does not constitute an acquisition of a significant amount of assets (as defined in Instruction 4 of Item 2.01) and, as such, pro forma financial information contemplated by Item 9.01 of Form 8-K is not required to be reported by Form 8-K with respect to such acquisition.
(d) Exhibits
Exhibit No. Description
2.1* Share Sale and Purchase Agreement, dated as of December 8, 2021, between Nanotron Technologies GmbH and the Shareholders of IntraNav GmbH.
104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Certain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Inpixon hereby undertakes to furnish copies of such omitted materials supplementally upon request by the U.S. Securities and Exchange Commission.
Nice pinch! Nice volume too. Keep it up $RCAT!!
Small cup and handle. Anything's possible here.
Hoping my .005's make some money. Thought this may see a bit more volume.
Up pressure building nicely. Inverted head and shoulders forming.
BXRX daily
Make the move back over the $ before Christmas would ya!!!?
Inpixon To Acquire IntraNav; Will Expand RTLS Capabilities with Industrial IoT Platform for Industry 4.0 Smart Factories, Smart Warehouses and Digital Supply Chains
Acquisition to Bring Established Relationships with Blue-Chip Companies and Market Leaders
Acquisition to Position Inpixon as a One-Stop-Shop for Comprehensive Location Intelligence Solutions for Both Corporate and Industrial Sides of an Organization
PALO ALTO, Calif., Dec. 9, 2021 /PRNewswire/ -- Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that it has signed a definitive agreement to acquire IntraNav GmbH (“INTRANAV”), a leading industrial IoT (IIoT), real-time location system (RTLS), and sensor data services provider. INTRANAV's customers are generally large enterprises with billions in annual revenue and include Siemens Energy, TB International, Festo, and PERI, as well as international industry leaders in the fields of agricultural and construction machinery, aerospace, intralogistics and manufacturing.
INTRANAV is a Germany-based industrial automation company specializing in advanced location-aware technologies to help organizations realize the benefits of Industry 4.0 including smart factories, smart warehouses, virtual manufacturing, paperless factories, virtual yard management, and digital supply chains. INTRANAV's flagship offering is its enterprise-class, multi-technology, RTLS IoT platform, INTRANAV.IO, which can consume, process, and present data from nearly any other device or system. INTRANAV's INTRALYTICS data-analytics software and INTRANAV.APP mobile and desktop apps complement the IoT platform. INTRANAV also offers a line of proprietary smart sensors including the tags for driverless transport systems, automated guided vehicles, smart pallets and more that can utilize UWB, RFID, GPS, Wi-Fi, and LTE cellular. Additional offerings with partners add NFC, BLE, and Wirepas Massive capabilities to the offering.
Inpixon-Intranav-IIoT-for-Industry-4
Siemens Energy's Key Expert of Manufacturing Processes and Senior Project Management Robert Diener, said, "We are using INTRANAV solutions for managing powder tracking in an additive manufacturing facility in Finspang, Sweden. The INTRANAV RTLS solution has helped us to greatly improve the transparency of our powder handling process on the shop floor.”
Stephan Schraml, head of technology center and lead plant scaffolding Günzburg, with PERI Werk Günzburg GmbH, one of the world’s largest manufacturers of formwork and scaffolding systems with 2020 revenues exceeding €11.5 billion, commented, “We are using INTRANAV solutions for indoor tracking of our transport racks for semi-finished goods and have found their solutions can help us to address supply chain issues in the production. We are now able to make predictions regarding the arrival time and quantity at the next workstation just in time. INTRANAV joining Inpixon sounds compelling, and I look forward to exploring the Inpixon location intelligence and app solutions for potential use for the corporate side of our business."
"This acquisition will put us at the heart of the fourth industrial revolution, commonly called Industry 4.0," noted Nadir Ali, CEO of Inpixon. "The manufacturing of goods and the processing of raw materials is in the midst of another wave of modernization, with Industry 4.0's digitalization of the horizontal and vertical value chains through automation and data exchange leveraging IoT and cloud computing. INTRANAV will bring new, comprehensive products and technologies, and a broad IP portfolio to strengthen our established RTLS product line. Importantly, with INTRANAV’s IoT platform, we will be connected to the end user for industrial solutions, much like our CXApp connects users through our corporate workplace solution, enabling us to deliver the exceptional experiences that power smart factories, smart warehouses, and smart corporate campuses. With INTRANAV, we believe Inpixon will be able to create significant opportunities for the growth of our business in this huge market."
INTRANAV was founded in 2014 by Ersan Günes, Chief Product & Technology Officer, and Gonzalo Ibarra, Chief Operating Officer. In 2020, Andreas Radix joined the management team as Chief Executive Officer to further scale up the business, and he and the founders will continue to lead the INTRANAV management team within Inpixon.
Andreas Radix of INTRANAV, said, "This is a very exciting time to join Inpixon. In recent months, our team has been uncovering more sales opportunities than we can reasonably address, and now, with Inpixon's resources and complementary products, I believe we will have an unmatched solution to capture the extraordinary opportunity in the industrial internet of things market.”
INTRANAV’s Ersan Günes added, “From our founding, we’ve been focused on developing cutting edge technology and supplying data-driven solutions to warehouses, distribution centers, and production lines that allow large, premier enterprises to optimize production and intralogistics. We're proud to bring our award-winning solutions to Inpixon and to make a significant and strategic enhancement to the Inpixon Indoor Intelligence platform."
Soumya Das, COO of Inpixon, commented, "I’m excited about Inpixon's prospects to grow substantially within the dynamic IIoT market. Inpixon offers a mature, full-stack location intelligence platform with the capability to support multiple use cases and industries, as recognized by independent researchers, which we believe will enable us to sell to not only the industrial side of the house but also to the corporate side, which can use our employee experience app and hybrid events platform, all underpinned with our intelligent maps, positioning technologies, and analytics."
INTRANAV’s research with customers has validated extraordinary time savings using INTRANAV solutions combined with integrations with leading ERP systems such as SAP. Savings versus traditional methods include the following:
Inbound: Unload, inventory and arrange goods: 23% faster
Storage: Identify and pick-up goods, find available shelf, unload: 37% faster
Outbound: Find, load, transport, unload at outbound point (preliminary data): 42% faster
Answers to frequently asked questions about this announcement can be found on the FAQ available here.
In accordance with the terms of a Share Sale and Purchase Agreement, dated December 8, 2021, Inpixon, through its wholly owned subsidiary, Nanotron Technologies, GmbH, as purchaser, will acquire 100% of the outstanding shares of IntraNav. The transaction is anticipated to close on or about December 9, 2021. Additional information regarding the transaction, including the terms, will be available in a Current Report on Form 8-K, which will be filed with the Securities and Exchange Commission in connection with this transaction.
About IntraNav
INTRANAV is a German real-time location & sensor data service provider for industrial platforms for the integration of the digital twin. With the digitization and allocation of real-time position data of industrial goods and transport vehicles with centimeter accuracy, the INTRANAV RTLS IoT platform contributes to a significant increase in efficiency and process reliability through the automation of logistics and production processes, such as Auto-ID solutions, paperless factory, AGV management, vehicle navigation, real-time material flow and shop floor management, and thus to the realization of the smart factory or digital supply chain. In addition to real-time data applications for the digital twin, INTRANAV also provides smart real-time location analyses from one platform suite, enabling companies to identify significant process optimizations and make data-based decisions. Customers and partners of INTRANAV are global companies such as Siemens Energy, PERI, Festo, SAP, Wirepas, and German Edge Cloud (GEC). For more information, please visit intranav.com.
About Inpixon
Inpixon® (Nasdaq: INPX) is the innovator of Indoor Intelligence™, delivering actionable insights for people, places and things. Combining the power of mapping, positioning and analytics, Inpixon helps to create smarter, safer, and more secure environments. The company’s Indoor Intelligence and mobile app solutions are leveraged by a multitude of industries to optimize operations, increase productivity, and enhance safety. Inpixon customers can take advantage of industry leading location awareness, RTLS, workplace and hybrid event solutions, analytics, sensor fusion and the IoT to create exceptional experiences and to do good with indoor data. For the latest insights, follow Inpixon on LinkedIn, Twitter, and visit inpixon.com.
Safe Harbor Statement
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19 on Inpixon's results of operations and global supply chain constraints, Inpixon’s ability to integrate the products and business from recent acquisitions into its existing business, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Inpixon’s technology, Inpixon's ability to maintain compliance with Nasdaq’s minimum bid price requirement and other continued listing requirements, the ability to obtain financing, competition, general economic conditions and other factors that are detailed in Inpixon's periodic and current reports available for review at sec.gov. Furthermore, Inpixon operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Inpixon disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.
Contacts
Inpixon
Media relations and general inquiries:
Inpixon
Email: marketing@inpixon.com
Web: inpixon.com/contact-us
Investor relations:
Crescendo Communications, LLC
Tel: +1 212-671-1020
Email: INPX@crescendo-ir.com
INTRANAV
Madlen Schuster
Digital Marketing Manager
Email: press@intranav.com
###
https://www.inpixon.com/company/news/inpixon-acquires-intranav-expands-rtls-industrial-iot-platform-for-industry-4-0-smart-factories-smart-warehouses-digital-supply-chains
Details to be posted in an 8-K.
okidoki
This puppy is looking to pinch
$MAPT
Excellent move reena969!!! I didn't even take a bite yesterday, or the day before. Got busy and didn't look back.
Member marking you.
NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer
Wed, December 8, 2021, 9:00 AM
In this article:
XSNX
-31.98%
Explore the topics mentioned in this article
CLEVELAND, OH / ACCESSWIRE / December 8, 2021 / NovAccess Global, Inc. (OTC PINK:XSNX) welcomes new Chief Financial Officer (CFO), Neil Laird.
"I am pleased to welcome Neil Laird to the management team," said Dr. Dwain Irvin, Chief Executive Officer, NovAccess Global.
Neil J. Laird is an experienced financial executive who works with emerging companies to provide accounting and finance-related services. Since 2017, he has worked with several technology and other companies as a consultant. Before that, he was the Chief Financial Officer of Mobileum Inc., a private company providing roaming and other solutions to the telecommunications industry. Prior to this, he was Chief Financial Officer at SumTotal Systems, a provider of enterprise learning management systems and before that, Chief Financial Officer at ADAC Laboratories, a provider of nuclear medicine and PET systems. Both were publicly traded companies. He also held senior management positions at Coherent Medical Lasers and Measurex Corporation. Mr. Laird has an MA from the University of Cambridge and qualified as a UK chartered accountant.
We thank ex-Chief Financial Officer, Mike Yukich who came out of retirement and helped NovAccess Global spin-off from the parent company Innovest Global.
About NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. The company owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.
Forward-Looking Statement
This press release and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
Investor Relations Contact:
Satya Chillara
Darrow Associates
(510) 396 -2776
schillara@darrowassociates.com
SOURCE: NovAccess Global Inc.
https://finance.yahoo.com/news/novaccess-global-inc-names-neil-140000350.html
We'll see if they can get their feet off the ground soon. My thinking anyway.
This market is just nuts. Just swinging a few bios and trying not to lose my you know what!!
ET setting up imo. Nice chart on SDC.
ET
Earnings Scheduled For December 8, 2021
might have to hold off on that one!!
Cheers Mav!!
Nice action, such a small float too.
About 3 weeks solid sideways. That's saying someone/s has/have been munching up shares big time!
The word convertible shows up 60 times.
I believe we'll be seeing a major financing through a new convertible structure (not yet in place).
But that's just my opinion and what many on the OTC end up doing as a last hail mary (that almost never works).
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793221007937/ipix_10q.htm
Leo already paid himself through the class B, don't think that won't happen again.... and again....
ET 8.35
ET daily
Keep a sharp eye on the convertibles. I think Leo will be taking plenty more. See if he manages to bring someone else in.
News excerpt... "1) Controlling who gets into the location
2) Managing behaviors within the space; and
3) Preparing to respond to incidents
ThinkIoT Back to Work Solutions support this three-step framework with a set of end-to-end, pre-tested and validated IoT solutions incorporating carefully selected and proven hardware and software partners, including CXApp, Inpixon, L Squared, Openpath, Relogix, and Viper Imaging.
Full article...
Lenovo Launches Internet of Things Solutions To Make The Workplace Safer During COVID-19
23 June 2020
ThinkIoT Solutions Simplify Workplace Preparation for Bringing Employees Back to the Office
RESEARCH TRIANGLE PARK, N.C., June 23, 2020 – Lenovo (HKSE: 992) (ADR: LNVGY) today announced IoT solutions for businesses returning to work after the coronavirus pandemic – ThinkIoT Back to Work Solutions. Lenovo has assembled an ecosystem of IoT solutions to help make it easier for customers to get back to work in offices without dealing with the hassle traditionally encountered in IoT projects. To that extent, Lenovo validates, deploys, and manages these end-to-end solutions globally in a set of turnkey offerings, especially important for large businesses with distributed locations. These are the first solutions from Lenovo’s Commercial Internet of Things Business Group, established in 2019 to help drive the company’s service-led transformation.
Lenovo provides a single point of accountability for customers across their Back to Work solutions. Lenovo tests each solution through a rigorous validation process that includes up to 140 steps covering security, serviceability, scalability, and reliability. Lenovo’s field network of more than 20,000 technicians handle deployment for all the solutions with minimal site disruption. With customers in more than 180 markets and expertise supporting more than 125 million devices, Lenovo provides leading solution monitoring and management to keep all these ThinkIoT Back to Work solutions running for customers.
Three-Step Framework for Back to Work
In a recent Lenovo survey in the U.S, 58% of respondents said their job shifted to remote work in response to Covid-19, and 88% say it’s important for their companies to deploy technology-based safety measures within their workplaces before they go back to work.1
Lenovo outlines a three-step framework with technology at its core to help make spaces safer and to accelerate business transformation for the long term.
1) Controlling who gets into the location
2) Managing behaviors within the space; and
3) Preparing to respond to incidents
ThinkIoT Back to Work Solutions support this three-step framework with a set of end-to-end, pre-tested and validated IoT solutions incorporating carefully selected and proven hardware and software partners, including CXApp, Inpixon, L Squared, Openpath, Relogix, and Viper Imaging.
These solutions help make workplaces safer as employees progress through the building:
Touchless Building Access: Modern access control that allows touchless access, phone-based authentication, easy cloud management, and integrations with legacy access control systems and IoT solutions. (Openpath)?
Elevated Temperature Screening: Thermal screening solutions using U.S. Food and Drug Administration cleared thermal cameras to identify elevated body temperature in individuals as they go through access points. (Viper Imaging)
Digital Signage and Policy Communication: Integrated digital communication and content management solution to effectively communicate policies and information to your workforce. (L Squared)
Safe Workspace Monitoring: Office occupancy monitoring solution with granularity to a seat level to comply with social distancing protocols and identify workspace utilization for target cleaning. (Relogix)
On-Premise Contact Tracing: Employee and visitor tracing using existing Wi-Fi network to monitor workspace zone health and enable a focused response in the event of an incident. (Inpixon)
Customers can choose what’s most important to them and mix and match solutions based on their desired outcomes. Lenovo serves as the one-stop shop for deploying and managing these Back to Work Solutions.
“For the past decade IoT solutions have promised great results but haven’t delivered,” said John Gordon, Lenovo’s President, Commercial Internet of Things. “Our purpose is simple – to overcome the logistical challenges of IoT systems to make them practical at scale. As the #1 PC maker, Lenovo is in the unique position to understand what it takes to manage electronic components spread around the world. We build on our global strength in services and supply chain and layer on industry-first IoT management software and a proven partner ecosystem to help customers finally get the value they’ve always wanted from IoT, quickly, and hassle free.”
At a time when IoT solutions are plentiful, single IoT solutions can easily require hundreds of thousands of sensors and end points when deployed across global site locations. Once companies start considering multiple IoT solutions, this challenge can easily reach millions of devices, limiting businesses from realizing the potential value of IoT. Lenovo recognizes and overcomes the business challenges associated with leveraging IoT solutions by identifying trusted solutions, deploying at scale, and managing across vendors and sites over time.
Availability2
ThinkIoT Back to Work Solutions are available beginning immediately in select regions through Lenovo sales channels.
For more information: visit www.lenovo.com/iot.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more visit https://www.lenovo.com, follow us on LinkedIn, Facebook, Twitter, YouTube, Instagram, Weibo and read about the latest news via our StoryHub.
LENOVO is a trademark of Lenovo. All other trademarks are the property of their respective owners. ©2020, Lenovo Group Limited.
1Survey conducted by Lenovo on June 8, 2020 of 1,000+ employees in the general population in the U.S.
2All offers subject to availability. Lenovo reserves the right to alter product offerings, features and specifications at any time without notice.
Press Contacts
Raleigh – Kristy Fair, krisfair@lenovo.com, (919)623-4493
Zeno Group – LenovoWWcorp@zenogroup.com
Partner Quotes
The CX App
“The future of work is connected – bridging physical and digital touchpoints through a mobile ecosystem of devices and IoT products that drive smart, automated experiences to the forefront of employee engagement,” said Leon Papkoff, CEO and Chief Strategist, The CXApp. “That’s why we’re excited to be a part of Lenovo’s ThinkIoT Back to Work Solution ecosystem – where The CXApp can bring everyone into a workplace experience platform that helps a distributed workforce feel confident and secure when they return to the office.”
Inpixon
“Inpixon is pleased to offer its Workplace Readiness™ solutions through Lenovo,” commented Nadir Ali, CEO of Inpixon (Nasdaq: INPX). “In today’s environment, businesses must invest in tools that enable them to adapt and address new challenges as they arise. Inpixon’s Indoor Intelligence technology helps organizations prepare to provide for the safety and security of their employees and visitors by leveraging their indoor data with tools that create visibility around social distancing protocols, support contact tracing efforts, and identify high priority zones for sanitizing. We’re excited to partner with Lenovo and help businesses reclaim their workplaces.”
L Squared
“With employees returning back to work, L Squared supports businesses with the right tools to create a safe and transparent environment for employees to flourish and do their best in,” said Ratnavel Gajendra, CEO, L Squared. “We are partnering with Lenovo to leverage their comprehensive ThinkIoT Back to Work Solutions to enable enterprises to deliver a connected employee experience by improving workplace culture and communication immediately.”
Openpath
“More than ever before, access control has become a crucial requisite to protecting the wellbeing and safety of our people, properties and IP,” said James Segil, President and Co-Founder of Openpath. “As companies focus on reopening their workplaces, Openpath is proud to partner with Lenovo to bring our unique “Wave To Unlock” hands-free access to the enterprise market. We want people to feel protected and at ease in the workplace, with technology that offers safety and peace-of-mind for all employees and visitors.”
Relogix
“Relogix intelligent workspace insights will help companies prepare and manage their return to work and understand the new patterns of work. We provide the insights needed to inform workspace design and other real estate decisions necessary to adapt to a very different working environment,” said Jeff Bennett, COO, Relogix. “As a key component of the Lenovo ThinkIoT Solutions, organizations will be able to deploy our technology with confidence knowing that all their global implementation and support needs will be handled by one of the most respected companies in the world.”
Viper Imaging
“We are proud to partner with Lenovo in providing ThinkIoT Back to Work Solutions,” said Rich Shannon, co-founder, Viper Imaging. “Lenovo’s objective of offering technology solutions for safe and seamless transitions back to work after the Coronavirus pandemic aligns with Viper’s mission statement – providing thermal solutions that increase efficiency, promote safety and effect positive environmental change. We know the implementation of thermal technology for elevated body temperature (EBT) detection is a vital piece in helping businesses stay safe as they get back to doing what they do best.”
Inpixon Reports Second Quarter 2020 Financial Results and
Provides Corporate Update...
We have secured certain key collaboration and reseller relationships, such as our relationship with Lenovo, allowing our solutions to be offered as part of their ThinkIoT Back to Work Solutions. We believe Lenovo’s global footprint and established relationships with large enterprise customers will complement our internal sales activities and assist in rapidly expanding awareness and accelerating adoption of our solutions.
? Announced Lenovo as an authorized reseller of Inpixon’s Workplace Readiness solutions, allowing our solutions to be offered as part of Lenovo’s ThinkIoT Back to Work Solutions, an ecosystem of IoT solutions that simplifies workplace preparation for bringing employees back to the office after closures due to COVID-19.
https://www.sec.gov/Archives/edgar/data/1529113/000121390020021883/ea125498ex99-1_inpixon.htm
================================
8-K
“As a result of these efforts, we are seeing strong traction for the adoption of our technology and solutions to address the demands of a new world, with new priorities. This is evidenced by the response that we have received from existing, new and potential customers, such as a global hotel chain and a major U.S. telecommunications company, as well as new partners, such our recently announced collaboration with Lenovo as part of its ecosystem of Think IOT Back to Work Solutions. As reopen plans continue to expand over the weeks and months to come, we are encouraged by a robust sales pipeline generated by the focus and efforts made during the second quarter that significantly exceeds our historical sales pipeline opportunities when compared to recent quarters.
https://www.marketwatch.com/investing/stock/inpx/SecArticle?guid=14263255
=============================
https://www.sec.gov/Archives/edgar/data/1529113/000162828021017145/0001628280-21-017145-index.htm
Filing Date
2021-11-15
Accepted
2021-11-15 17:20:56
Period of Report
2021-06-30
However, it's Dec 31-2019 - 06/30/20020. Interesting.
So, where is Lenovo with Inpixion now?
No mention in their 6/30/2021 quarterly...
Filing Date
2021-08-16
Accepted
2021-08-16 17:16:40
Documents
123
Period of Report
2021-06-30
https://www.sec.gov/ix?doc=/Archives/edgar/data/1529113/000162828021017145/inpx-20210630.htm
Very good question JaneyH.
Stocks have been getting deflated like crazy the past couple of weeks. At least that's what I've been seeing.
Take a look at SYN .32 BXRX .345
SYN daily
BXRX daily
Certainly nothing exciting but for a market day as red as it WAS $HEPA held up very nicely. The chart had the wind taken out of it a bit so nothing exciting there either. See how next week sets up for the Santa rally.
Excellent market theory of what's happening. When things start looking this edgy I like to start watching the transportation index. $TRAN just broke below its 50 dma and is likely heading to the 200 dma for support. DIA is nearing a major support level right here at 34k which imo it looks to crack. With the VIX setting up to enter the RSI power zone I wouldn't be surprised to see our daily volatility get even more crazy.
Santa rally could turn things around if it can happen against all the new COVID threats.
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Thermostabilized single vial vaccine targeting Sudan and Marburg filoviruses protects 100% of non-human primates against lethal Sudan ebolavirus challenge
https://ir.soligenix.com/2021-12-02-Soligenix-Announces-Successful-Protection-using-a-Bivalent-Thermostabilized-Filovirus-Vaccine
AWESOME!!
This is my watch list for lithium...
Symbol Bid Ask Price Chg ($) Chg (%) Open High Low Volume
LITH
0.51 1.10 0.0001 0.00 0.00% -- -- -- --
LTUM
0.251 0.2894 0.26 -0.0152 -5.52% 0.27 0.27 0.251 335.78K
AMLM
0.272 0.284 0.2834 -0.0176 -5.85% 0.2925 0.309 0.2705 248.32K
EOSE
9.05 9.25 9.06 -0.89 -8.94% 10.22 10.22 9.04 562.79K
LTHM
28.35 28.60 28.35 -1.94 -6.40% 30.87 31.69 28.49 3.09M
LAC
34.60 35.40 34.60 -4.71 -11.98% 37.64 38.31 34.88 9.46M
ENR
36.82 38.26 37.24 0.05 0.13% 37.72 38.29 37.15 624.22K
SQM
60.59 61.69 61.73 -0.53 -0.85% 63.69 64.88 60.65 1.17M
CHWY
66.01 66.49 66.49 -1.77 -2.59% 68.62 69.38 65.32 6.92M
PSX
68.41 69.80 68.67 -0.50 -0.72% 71.40 71.8348 68.63 3.98M
JCI
74.57 75.39 74.97 0.21 0.28% 76.39 77.93 74.93 3.69M
LIT
91.00 91.50 91.35 -1.64 -1.76% 93.88 94.37 91.23 1.39M
FMC
92.15 100.10 100.10 -0.09 -0.09% 102.60 104.34 100.14 788.52K
ALB
260.00 269.84 260.00 -6.49 -2.44% 270.01 276.00 259.80 1.25M
5:52:53 pm ET 12/1/21
Just so you know I haven't done much DD but these are from my quick scan with only a quick review mostly on finviz. I need to look at them more closely and now may be the time to do so.
I still see more market downside though there is this...
There are cracks everywhere...
I posted this on Monday....
"Check out the bounce on the YEN. The markets continue to over perform as the Feds continue to dig our hole deeper and deeper.
Certainly debt based market can perform on "future expectation" though on thin air? It worked for Japan into negative interest rates but it isn't "ever ending".
The clock is ticking. And the inflation is only just beginning. Those that have been getting "free money" will feel the pinch even more, especially if they haven't been able to squirrel some away into savings. Though Biden will likely continue the handouts.
Crazy. No doubt about it.
https://finviz.com/futures_charts.ashx?p=d1&t=6J "
Many of the stocks I'm watching are still breaking support levels. I've been nibbling a few here and there though as I look more and more my charts are going further and further out. I'm thinking this pull back is far from over.
There are cracks everywhere